CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

NCT03904251 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

13

Enrollment

OTHER

Sponsor class

Stopped slow accrual

Conditions

Acute Myelogenous Leukemia

Interventions

DRUG: Gemtuzumab Ozogamicin
DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]